This shows that while mTOR was effectively inhibited, the cellular pathophysiology was not fully reversed and suggests use of additional combination therapies tailored to the clinical picture of TSC patients (Fig. 4f). The gene discussed is MTOR; the disease is tuberous sclerosis.